Compare Repligen Corporation Common Stock (RGEN) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Charles Schwab Corporation Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Charles Schwab Corporation Common Stock trades at $98.05 (market cap $165.91B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 14.9× Repligen Corporation Common Stock's market cap, and Charles Schwab Corporation Common Stock pays a 1.33% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Charles Schwab Corporation Common Stock for 86 Days on average.
| RGEN | SCHW | |
|---|---|---|
Market Cap | $11.14B | $165.91B |
Volume | 1,259,263 | 6,860,399 |
Sector | Health | Financials |
52-Week High | $194.57 | $113.65 |
52-Week Low | $102.87 | $85.35 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $11.02B | $152.35B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Charles Schwab (SCHW) trades at $96.80, down 0.27% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported record quarterly revenue of $7.08 billion in Q3 2026 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.69 price target, representing 25% upside potential from current levels.
SCHW demonstrates robust financial health with 38.79% net margins and 22.45% ROE, though technical weakness and competitive pressures in brokerage services present near-term challenges. The stock offers attractive valuation at 17.48x P/E with strong earnings momentum, but investors should monitor interest rate sensitivity and market volatility impacts on trading volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
